MYC has been shown to preferentially bind to the HIF2A gene promoter in mouse Sca1C+ cancer stem cells (CSCs) in a MYC-driven mouse T-cell leukemia model and the equivalent ATP-binding cassette superfamily G member 2+ CSC population in human acute lymphoblastic lymphoma, and activate HIF2A expression [124]. This evidence concerns the gene EPAS1 and cancer.